# Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

> **NCT00639769** · PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 41 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00639769
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2007-05
- **Final completion:** 2008-07
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2012-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00639769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00639769, "Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00639769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*